NCT03303924View on ClinicalTrials.gov

Study to Determine and Compare Plasma and Intrapulmonary Concentrations of ETX2514 and Sulbactam in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 21, 2017

Primary Completion Date

October 17, 2017

Study Completion Date

October 26, 2017

Conditions

Healthy

Interventions

DRUG

ETX2514 and sulbactam

Each subject will receive three doses of of ETX2514 1.0 g and sulbactam 1.0 g via intravenous (IV) infusion administered every 6 hours with each drug infused over 3 hours

Trial Locations (1)

85006

Pulmonary Associates, PA, Phoenix